• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Belamaf Regimen Improves Progression-Free Survival in Myeloma

by | Jun 3, 2024 | Uncategorized

Source: CureToday articles Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse. Read More

Isatuximab confers ‘impressive’ delay in multiple myeloma progression

by | Jun 3, 2024 | Uncategorized

CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.Additionally, patients with...

Regimen confers ‘clinically meaningful’ PFS benefit in relapsed multiple myeloma

by | Jun 2, 2024 | Uncategorized

CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with standard care for patients with relapsed or refractory multiple myeloma, according to data presented at ASCO Annual Meeting.Researchers reported a 47%...

Blenrep Combo Lengthens Time to Progression in Relapsed, Refractory Myeloma

by | Jun 2, 2024 | Uncategorized

Source: CureToday articles Blenrep, Pomalyst and dexamethasone improved progression-free survival compared to Velcade, Pomalyst and dexamethasone in patients with relapsed/refractory myeloma. Read More

FDA Grants Priority Review to Sarclisa for Multiple Myeloma

by | May 29, 2024 | Uncategorized

Source: CureToday articles Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants. Read More

MRD Status May Help Personalize Myeloma Treatment

by | May 22, 2024 | Uncategorized

Source: CureToday articles Using tests to identify minimal residual disease may help determine how much treatment patients with multiple myeloma require. Read More
« Older Entries
Next Entries »

Recent Content

  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
  • VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
  • Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
  • Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
  • Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT